JP2025512469A5 - - Google Patents
Info
- Publication number
- JP2025512469A5 JP2025512469A5 JP2024560676A JP2024560676A JP2025512469A5 JP 2025512469 A5 JP2025512469 A5 JP 2025512469A5 JP 2024560676 A JP2024560676 A JP 2024560676A JP 2024560676 A JP2024560676 A JP 2024560676A JP 2025512469 A5 JP2025512469 A5 JP 2025512469A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- light chain
- seq
- heavy chain
- constant region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263331716P | 2022-04-15 | 2022-04-15 | |
| US63/331,716 | 2022-04-15 | ||
| PCT/US2023/065764 WO2023201324A1 (en) | 2022-04-15 | 2023-04-14 | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512469A JP2025512469A (ja) | 2025-04-17 |
| JP2025512469A5 true JP2025512469A5 (enExample) | 2026-02-02 |
Family
ID=88330384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024560676A Pending JP2025512469A (ja) | 2022-04-15 | 2023-04-14 | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250249116A1 (enExample) |
| EP (1) | EP4508091A1 (enExample) |
| JP (1) | JP2025512469A (enExample) |
| KR (1) | KR20250004769A (enExample) |
| CN (1) | CN119256008A (enExample) |
| AU (1) | AU2023253710A1 (enExample) |
| CA (1) | CA3248961A1 (enExample) |
| IL (1) | IL315944A (enExample) |
| MX (1) | MX2024012737A (enExample) |
| WO (1) | WO2023201324A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2023283623A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG186451A1 (en) * | 2010-07-12 | 2013-01-30 | Covx Technologies Ireland Ltd | Multifunctional antibody conjugates |
| MX2023000958A (es) * | 2020-07-23 | 2023-04-14 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de estos para el tratamiento de la distrofia miotonica. |
-
2023
- 2023-04-14 WO PCT/US2023/065764 patent/WO2023201324A1/en not_active Ceased
- 2023-04-14 CN CN202380034350.7A patent/CN119256008A/zh active Pending
- 2023-04-14 US US18/856,247 patent/US20250249116A1/en active Pending
- 2023-04-14 CA CA3248961A patent/CA3248961A1/en active Pending
- 2023-04-14 IL IL315944A patent/IL315944A/en unknown
- 2023-04-14 KR KR1020247037612A patent/KR20250004769A/ko active Pending
- 2023-04-14 JP JP2024560676A patent/JP2025512469A/ja active Pending
- 2023-04-14 AU AU2023253710A patent/AU2023253710A1/en active Pending
- 2023-04-14 EP EP23789168.4A patent/EP4508091A1/en active Pending
-
2024
- 2024-10-14 MX MX2024012737A patent/MX2024012737A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL315944A (en) | Muscle targeting complexes and uses thereof for treating myotonic dystrophy | |
| IL316143A (en) | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy | |
| JP2025512468A5 (enExample) | ||
| IL309936A (en) | Muscle targeting complexes and formulations for treating dystrophinopathies | |
| JP2024540199A5 (enExample) | ||
| IL316206A (en) | Dosage of muscle targeting complexes for the treatment of myotonic dystrophy | |
| IL309910A (en) | Muscle targeting complexes and their uses for the treatment of myotonic dystrophy | |
| JP2023509793A5 (enExample) | ||
| JP2024503609A5 (enExample) | ||
| IL320340A (en) | Muscle targeting complexes and uses thereof for skipping exon 45 of a dmd gene | |
| JP2024524222A5 (enExample) | ||
| JP2024527362A5 (enExample) | ||
| JP2024534488A5 (enExample) | ||
| JP2025512464A5 (enExample) | ||
| JP2024525611A5 (enExample) | ||
| JP2023510350A5 (enExample) | ||
| JP2023535078A5 (enExample) | ||
| JP2024525610A5 (enExample) | ||
| IL317871A (en) | Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy | |
| IL312142A (en) | Muscle targeting complexes for the treatment of dystrophinopathy | |
| JP2024525612A5 (enExample) | ||
| JP2024160045A5 (enExample) | ||
| IL311507A (en) | Dosing of muscle targeting complexes for the treatment of dystrophinopathy | |
| IL312170A (en) | Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy | |
| JP2024525613A5 (enExample) |